[go: up one dir, main page]

MX9802764A - Promotor homologo fuerte procedente de un hamster. - Google Patents

Promotor homologo fuerte procedente de un hamster.

Info

Publication number
MX9802764A
MX9802764A MX9802764A MX9802764A MX9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A
Authority
MX
Mexico
Prior art keywords
hamsters
intensive
promoter obtained
homologous promoter
promoter
Prior art date
Application number
MX9802764A
Other languages
English (en)
Inventor
Barbara Enenkel
Frank Gannon
Klaus Bergemann
Wolfgang Noe
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of MX9802764A publication Critical patent/MX9802764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

El invento concierne a un promotor homologo fuerte procedente de un hámster. Especialmente, se trata en tal caso del promotor del gen, que codifica la proteína de fusion de ubiquitina-S27a. El promotor se puede utilizar para procedimientos destinados a la preparacion de productos génicos heterologos en células cultivadas, especialmente en células de CHO.
MX9802764A 1995-10-24 1998-04-07 Promotor homologo fuerte procedente de un hamster. MX9802764A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19539493A DE19539493A1 (de) 1995-10-24 1995-10-24 Starker homologer Promotor aus Hamster

Publications (1)

Publication Number Publication Date
MX9802764A true MX9802764A (es) 1998-11-30

Family

ID=7775593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9802764A MX9802764A (es) 1995-10-24 1998-04-07 Promotor homologo fuerte procedente de un hamster.

Country Status (11)

Country Link
US (1) US6063598A (es)
EP (2) EP0857211B1 (es)
JP (2) JP3966903B2 (es)
AT (1) ATE355370T1 (es)
CA (1) CA2234071C (es)
DE (2) DE19539493A1 (es)
DK (1) DK0857211T3 (es)
ES (1) ES2281905T3 (es)
MX (1) MX9802764A (es)
PT (1) PT857211E (es)
WO (1) WO1997015664A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
EP1624067A3 (en) * 2000-09-18 2006-03-15 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
US6667174B2 (en) * 2000-09-18 2003-12-23 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
DK1404872T3 (da) * 2001-07-04 2007-02-19 Chromagenics Bv Fremgangsmåde til selektion af en DNA-sekvens med transkriptionsmodulerende aktivitet med en vektor indeholdende et element med en gentranskriptionsundertrykkende aktivitet
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
DE10256083A1 (de) 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) * 2003-11-10 2005-05-12 Wojtek Auerbach Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
NZ592891A (en) * 2005-06-20 2013-02-22 Cadila Healthcare Ltd Expression vector and methods of producing high levels of proteins
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PL2771031T3 (pl) 2011-10-28 2018-09-28 Prothena Biosciences Limited Co. Humanizowane przeciwciała rozpoznające alfa-synukleinę
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
US9989540B2 (en) 2013-05-10 2018-06-05 The Regents Of The University Of California Diagnostic and monitoring system for Huntington's disease
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
ES2780692T3 (es) * 2013-12-31 2020-08-26 Proteonic Biotechnology Ip Bv Constructo y secuencia para la expresión genética mejorada
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
CN107438623B (zh) 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP6983073B2 (ja) 2015-05-18 2021-12-17 ザイムトロニクス インコーポレイテッド 磁気固定化殺菌性酵素
CA2992261A1 (en) 2015-07-15 2017-01-19 Zymtronix, Llc Automated bionanocatalyst production
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
KR102618424B1 (ko) 2016-07-11 2023-12-26 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
WO2018034877A1 (en) 2016-08-13 2018-02-22 Zymtronix, Llc Magnetically immobilized biocidal enzymes and biocidal chemicals
WO2018132783A1 (en) 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
AU2017434556B2 (en) 2017-09-28 2024-11-14 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
JP7453961B2 (ja) 2018-09-05 2024-03-21 ザイムトロニクス キャタリティック システムズ インコーポレイテッド 磁気骨格上の固定化酸素及びミクロソーム
SG11202104441QA (en) 2018-11-26 2021-06-29 Forty Seven Inc Humanized antibodies against c-kit
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
US12221622B2 (en) 2019-05-10 2025-02-11 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
EP3990627A4 (en) 2019-06-26 2023-07-19 The Regents of The University of California SIRP-ALPHA SILENCED NATURAL KILLER CELLS (NK)
JP2022543112A (ja) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
US20230272429A1 (en) 2020-01-13 2023-08-31 Sana Biotechnology, Inc. Modification of blood type antigens
CA3165076A1 (en) 2020-01-17 2021-07-22 Ryan Clarke Safety switches for regulation of gene expression
WO2021195426A1 (en) 2020-03-25 2021-09-30 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
US20220049226A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
IL303473A (en) 2020-12-31 2023-08-01 Sana Biotechnology Inc Methods and compositions for modulating car-t activity
US20240252642A1 (en) 2021-05-19 2024-08-01 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
US20240425820A1 (en) 2021-08-11 2024-12-26 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024531234A (ja) 2021-08-11 2024-08-29 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法のための遺伝子改変された初代細胞
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025059491A2 (en) 2023-09-15 2025-03-20 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025059515A2 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Cell penetrating agents and uses thereof
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof

Also Published As

Publication number Publication date
DE59611420D1 (de) 2007-04-12
PT857211E (pt) 2007-03-30
JP3966903B2 (ja) 2007-08-29
US6063598A (en) 2000-05-16
EP1803815A3 (de) 2007-08-29
JP2006320330A (ja) 2006-11-30
ATE355370T1 (de) 2006-03-15
ES2281905T3 (es) 2007-10-01
WO1997015664A1 (de) 1997-05-01
EP0857211B1 (de) 2007-02-28
JPH11513572A (ja) 1999-11-24
CA2234071A1 (en) 1997-05-01
EP0857211A1 (de) 1998-08-12
DE19539493A1 (de) 1997-04-30
EP1803815A2 (de) 2007-07-04
CA2234071C (en) 2003-01-21
DK0857211T3 (da) 2007-03-26

Similar Documents

Publication Publication Date Title
MX9802764A (es) Promotor homologo fuerte procedente de un hamster.
DK0770139T3 (da) En svamp, hvor areA-genet er blevet modificeret, samt et areA-gen fra aspergillus oryzae
AU6724194A (en) Nucleotide sequences for the control of the expression of dna sequences in a cellular host
BG102016A (en) Method for the diagnostics of schizophrenia
EP1020528A3 (en) Method for producing secreted proteins
PL341760A1 (en) Expression cloning in mildew fungi
PL345408A1 (en) Overexpression of phytase genes in yeast systems
AU4355697A (en) High level expression of proteins
AU1383695A (en) An enzyme feed additive and animal feed including it
WO1994018316A3 (en) Apolipoprotein b mrna editing protein compositions and methods
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
EP0700995A3 (en) Process for the production of proteins
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
MX9705039A (es) Genes y proteinas de muerte celular programada.
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
AU3802595A (en) Tripeptidyl aminopeptidase
AU6724794A (en) GRB3-3 gene, its variants and their uses
SE8101665L (sv) Polypeptidframstellning
EP0776972A4 (en) GENE ENCODING THE IgG-Fc-BINDING PROTEIN
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
AU1720397A (en) Recombinant expression of s-layer proteins
EP1010761A4 (en) UNCOMFORTABLE
GB9726897D0 (en) Process
NZ334744A (en) Method for determining expression of aberrant forms of APC protein

Legal Events

Date Code Title Description
FG Grant or registration